Heart failure & cardiomyopathies
Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum
Authors' conclusion
The relative benefits of dapagliflozin were consistent in Black and White patients across the range of left ventricular ejection fraction, with greater absolute benefits in Black patients.
Study context
- Population
- Patients with heart failure (HF) across the EF spectrum (HFrEF in DAPA-HF; HF with mildly reduced EF/HFpEF in DELIVER) randomised in the Americasrandomised in the Americas
- Participants
- 3,526 patients
- Comparison
- Dapagliflozin vs placebo, in Black and White patients
- Blackn = 381
- Whiten = 2,626reference
- Primary endpoint
- Worsening HF or CV death
Methodological detailsplacebo-controlled, subgroup analysis by race, Americas only
- Placebo-controlled
- Subgroup analysis by race
- Americas only
Primary result
As reported in the abstract
Worsening HF or CV death: dapagliflozin vs placebo, by race
Dapagliflozin vs PlaceboHazard ratio (95% CI)
Black patients
0.69(0.47–1.02)
White patients
0.73(0.61–0.88)
- NNT to prevent one event over median follow-up, White
- 17
- NNT to prevent one event over median follow-up, Black
- 12
Further findings
Rate, per 100 person-years
| Outcome | Black | White | Adjusted HR (95% CI) | |
|---|---|---|---|---|
| Worsening HF or CV death, Blackvs White | 16.8 (95% CI 13.8–20.4) | 11.6 (95% CI 10.6–12.7) | 1.27 (1.01–1.59) | |
| 0.512Adjusted hazard ratio (log scale) |
Benefit of dapagliflozin across LVEF range
- Beneficial effects consistent across LVEF range in Black and White patients
Safety
Safety of dapagliflozin across LVEF range
- Favorable safety profile consistent across LVEF range in Black and White patients
Original publication
Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum. JACC Heart Fail. Published 1 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →